 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3388 News |  |
| «12...3637383940414243444546...4849» |
- || Contepo (ZTI-01) / Nabriva, Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Review, Journal: Spatio-Temporal Distribution of Acinetobacter baumannii in Germany-A Comprehensive Systematic Review of Studies on Resistance Development in Humans (2000-2018). (Pubmed Central) - Mar 13, 2020
Increased awareness, extensive study of mechanisms of resistance and development of alternative strategies for treatment are required. One-Health genomic surveillance is needed to understand the dynamics of spread, to identify the main reservoirs and routes of transmission and to develop targeted intervention strategies.
- | meropenem / Generic mfg., Daewon Pharmaceutical, Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Journal: In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012-2015. (Pubmed Central) - Mar 12, 2020
Overall, clinical isolates of Enterobacteriaceae collected in Latin America from 2012 to 2015 were highly susceptible to ceftazidime-avibactam, including isolates that exhibited resistance to ceftazidime, meropenem, colistin, or an MDR phenotype. Country-specific variations were noted in the susceptibility of P. aeruginosa isolates to ceftazidime-avibactam.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Clinical data, Journal: Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli. (Pubmed Central) - Mar 11, 2020
No severe adverse events related to CAZ-AVI occurred. CAZ-AVI treatment of CRKP/ CRPA infection in LT recipients was associated with high rates of clinical success, survival, and safety, but recurrent CRKP/CRPA infections in the respiratory tract did occur.
- ||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
New #AusPAR for #Zavicefta (#ceftazidime/avibactam) for the treatment of #infections: https://t.co/0186hD12yK (Twitter) - Mar 9, 2020
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae. (Pubmed Central) - Mar 9, 2020
Multivariate analysis of the 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index >3, and recent mechanical ventilation as independent predictors of mortality, whereas receipt of CAZ-AVI was the sole independent predictor of survival. CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia.
- || Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations. (Pubmed Central) - Mar 9, 2020
This review focuses on differences in in vitro activity of these agents as a function of mechanism of carbapenem resistance, the clinical data supporting their superiority over colistin-based therapy, and the differences between agents with regards to propensity for selection of resistance. Furthermore, considerations and recommendations for hospital formularies and antibiotic stewardship programs regarding positioning of these agents are discussed.
- | Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Journal, HEOR: Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. (Pubmed Central) - Mar 5, 2020
The incremental cost-effectiveness ratio was € 8,039/QALY which is well below the willingness-to-pay threshold of € 30,000/QALY in Italy. The model results showed that CAZ-AVI is expected to be a cost-effective treatment compared to imipenem for cUTI in Italy.
- | Journal: Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms. (Pubmed Central) - Mar 2, 2020
However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.
- || meropenem / Generic mfg., Daewon Pharmaceutical
Clinical, Journal: Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). (Pubmed Central) - Mar 2, 2020
Colistin (100.0% susceptible), ceftolozane-tazobactam (98.7% susceptible), ceftazidime-avibactam (98.2% susceptible), amikacin (97.9% susceptible), and tobramycin (95.6% susceptible) were very active against Pseudomonas aeruginosa. Among S. aureus isolates, 57.8% were oxacillin-susceptible.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran. (Pubmed Central) - Mar 1, 2020
Ceftazidime-avibactam and ceftolozane-tazobactam showed high activity against the P. aeruginosa isolated from patients with UTI in Iran. The low rate of resistance to the antibiotics is also alarming and should be considered to avoid further spreading of the antibiotic resistance among the P. aeruginosa and the other bacteria.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Review, Journal: Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-Abdominal Infections, Complicated Urinary Tract Infections and Nosocomial Pneumonia. (Pubmed Central) - Feb 29, 2020
Subgroup simulations for individual Phase III patients showed that the dosage regimen was robust, with high target attainment (>95%) against MICs ≤8 mg/l achieved regardless of older age, obesity, augmented renal clearance or severity of infection. This review summarizes how the approved ceftazidime-avibactam dosage regimens were developed and validated using PK/PD targets, population PK modeling, and PTA analyses.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Thanks. There is this FDA list of drug shortages https://t.co/gaBqwBHzH5 and not sure if the Ceftazidime-Avibactam is related to the outbreak. (Twitter) - Feb 28, 2020
- ||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
For all my friends in medicine that is Ceftazidime-Avibactam (Avycaz) a drug we use to treat highly resistant bacteria. It is made by @pfizer. Wonder if others on #IDtwitter have heard this? @CarlosdelRio7 @DrJeanneM @Armstrws @E_Stenehjem @StanDeresinski (Twitter) - Feb 28, 2020
- ||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Pricing, Reimbursement: On one hand, new AMR Gram neg agents are economically inviable given size of US market. On other, instability of supply limits access to new agents. Failure of abx development is not just about pt numbers, costs and reimbursement. First CAZ-AVI shortage cost $300M & 18 m lag. (Twitter) - Feb 28, 2020
- ||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical: Take-home is generally in line w our earlier OFID report on use of Caz-Avi and Polymyxins, which was based on IQVIA prescription data. Jeff's data show bit more drop-off in colistin use than our's. His data are patient-level, rather than extrapolations https://t.co/4ZIkx1i8RI (Twitter) - Feb 28, 2020
- |||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
cJust out from Jeff Strich et al. at NIH, w editorial by Mike Satlin. Caz-Avi and Colistin use in US using Agilent database, showing, as Mike says, "languid" uptake of the former in first 3+ yrs & still sizable colistin use. https://t.co/vtDSDPWIDQ https://t.co/G4gAjYmP79 (Twitter) - Feb 28, 2020
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Journal: In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa: Results from a Multicenter Study in China, 2017. (Pubmed Central) - Feb 26, 2020
Overall, both ceftazidime-avibactam and ceftolozane-tazobactam were highly active against clinical isolates of Enterobacteriaceae and P. aeruginosa collected recently across China. And ceftazidime-avibactam was superior against Enterobacteriaceae than ceftolozane-tazobactam, whereas the latter showed better effect against P. aeruginosa.
- || Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD), arbekacin (NPC-14) / Nobelpharma, Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
I've heard of them. Or one. But only "heard". Because I trained with Bob Arbeit. Of arbekacin fame. 🤷🏼♀️ Are any of the new combos available in your country? Caz/avi, mero/vab or imi/rel? Erava? If yes, I would use those for CRE over AGs. (Twitter) - Feb 26, 2020
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. (Pubmed Central) - Feb 25, 2020
In patients treated with ceftazidime-avibactam for CRE infections, mortality risk scores demonstrated variable performance. Modifications to scoring systems to more accurately predict outcomes in the era of novel antibiotics are warranted.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Edit to earlier tweet: caz avi point estimate 7.3% worse with 95% CI from 27.3% worse to 12.6% better. Had reversed numbers in earlier tweet. (Twitter) - Feb 24, 2020
- || Recarbrio (relebactam/imepenem/cilastatin) / Merck (MSD), Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
The data we have show that ATM + M/V should be equivalent to ATM + caz-avi except for OXA 48 like producers. Our eccmid poster is on atm +imi/rel and we'll have quite a bit of steno data coming very soon including CFDC. Also against MBL pseudos https://t.co/ufGkofTlZu (Twitter) - Feb 24, 2020
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
What happened to caz-avi? (Twitter) - Feb 24, 2020
- || Clinical, Review, Journal: Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. (Pubmed Central) - Feb 24, 2020
A section is devoted to reviewing upcoming active drugs such as imipenem-relebactam, cefepime-zidebactam, cefiderocol, and murepavadin. Finally, other therapeutic strategies, such as use of vaccines, antibodies, bacteriocins, anti-quorum sensing, and bacteriophages, are described as future options.
- | Vabomere (meropenem/vaborbactam) / Melinta Therap
Preclinical, Journal: Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae. (Pubmed Central) - Feb 22, 2020
Vaborbactam inhibited both wild-type and variant KPC enzymes. On the other hand, KPC-producing K. pneumoniae with ompK36 mutations displayed higher meropenem-vaborbactam MICs than isolates with wild-type ompK36 Susceptibility testing with bioMérieux gradient strips most closely aligned with broth microdilution methods.
- | Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Journal: Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. (Pubmed Central) - Feb 21, 2020
The outbreak strain was sequence type (ST)147 and co-produced KPC-2 and the novel plasmid-borne Vietnamese extended-spectrum β-lactamase (VEB)-25 harbouring a K234R substitution associated with CZA resistance. Epidemiological investigations revealed that the resistance was probably acquired by horizontal transmission independently from previous CZA exposure.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. (Pubmed Central) - Feb 15, 2020
Epidemiological investigations revealed that the resistance was probably acquired by horizontal transmission independently from previous CZA exposure. Ceftazidime-avibactam may be a valuable therapeutic option for serious infections due to GNB other than CRE.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Review, Journal: Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes. (Pubmed Central) - Feb 14, 2020
Increase of faecal carriers and presence of carbapenemases in the so-called high-risk clones have boosted the persistence and dissemination of CPE. One of these clones, the ST307 K. pneumoniae, has been associated with the spread of KPC carbapenemases and emergence of KPC variants conferring resistance to ceftazidime-avibactam combination.
- ||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical: Great write up! I just did a formulary review on this for our hospital system. We were interested to see if it has utility in PSA isolates resistant to TOL/TAZ and/or CAZ/AVI. This article says yes https://t.co/28nQuM8vvz (Twitter) - Feb 13, 2020
- || aztreonam-avibactam (PF-06947387) / Allergan, Pfizer, Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing Enterobacterales During a Regional Outbreak. (Pubmed Central) - Feb 13, 2020
In most cases, aztreonam-avibactam is active in vitro. Ceftazidime-avibactam plus aztreonam may represent a feasible therapeutic option.
- ||| Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical: Would like to see data with TOL-TAZ-R Pseudomonas isolates. We would have used it a few times in the post-approval, pre-availability vacuum if possible and active. I can see small hospitals adding to formulary in lieu of CAZ-AVI or M-V but only after finding a way to test easily (Twitter) - Feb 13, 2020
- || Review, Journal: Carbapenem-Sparing Strategies for ESBL Producers: When and How. (Pubmed Central) - Feb 10, 2020
An important point of the review focuses on piperacillin-tazobactam as the agent arousing the most debate. The most available data regarding non-carbapenem β-lactams (i.e., ceftolozane-tazobactam, ceftazidime-avibactam, temocillin, cephamycins and cefepime) are also thoroughly presented as well as non β-lactams (i.e., aminoglycosides, quinolones, tigecycline, eravacycline and fosfomycin).
- | Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Journal: In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries. (Pubmed Central) - Feb 10, 2020
Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. The results of this study underline the potential therapeutic role of CZA in Latin America.
- || Review, Journal: Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. (Pubmed Central) - Feb 10, 2020
Novel β-lactam/β-lactamase inhibitors, plazomicin, and cefiderocol give the clinician options that were once not available. Utilizing these options is of the utmost importance when treating carbapenem-resistant Enterobacterales.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Review, Journal: Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences. (Pubmed Central) - Feb 8, 2020
Although not specifically approved for neutropenic and/or cancer patients, these drugs are used in this setting due to increasing rates of infections caused by MDR Gram-negative bacteria. The aim of this review is to describe the actual evidence from scientific literature about the "real-life" use of these two novel drugs in patients with hematological malignancies and infections caused by MDR Gram-negative bacteria.
- || Zavicefta (ceftazidime + avibactam) / Pfizer, Allergan
Clinical, Journal: Successful treatment of a bacteremia due to NDM-1-producing Morganella morganii with Aztreonam and Ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. (Pubmed Central) - Feb 7, 2020
The aim of this review is to describe the actual evidence from scientific literature about the "real-life" use of these two novel drugs in patients with hematological malignancies and infections caused by MDR Gram-negative bacteria. Worldwide spread of multiresistant bacteria, especially carbapenemase-producing Enterobacteriaceae, can lead to situations for which no antibiotic therapy option is available.….
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: EZTEAM: Real-World Observational Study Of Zavicefta to Characterize Use Patterns (clinicaltrials.gov) - Feb 6, 2020
P=N/A, N=1030, Recruiting, Sponsor: Pfizer
Worldwide spread of multiresistant bacteria, especially carbapenemase-producing Enterobacteriaceae, can lead to situations for which no antibiotic therapy option is available.…. Trial completion date: Dec 2019 --> Mar 2022 | Trial primary completion date: Dec 2019 --> Mar 2022
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] German multi-centre study on standardised in vitro testing of ceftazidime-avibactam against extensively drug-resistant clinical Pseudomonas aeruginosa isolates from 2017-2019 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5353;
- [VIRTUAL] Comparative in vitro activity of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam against susceptible and resistant Pseudomonas aeruginosa ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5350;
- Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime-avibactam, meropenem-vaborbactam and comparators against these isolates ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5348;
- aztreonam-avibactam (PF-06947387) / Pfizer, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro susceptibility of carbapenem-resistant Enterobacteriaceae from the Arabian Peninsula to ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5347;
- [VIRTUAL] Activity of imipenem-relebactam and meropenem-vaborbactam against ceftazidime-avibactam-resistant Klebsiella pneumoniae isolates producing KPC carbapenemases ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5346;
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates collected from US medical centres in 2016-2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5345;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro activity of ceftazidime-avibactam and comparators against isolates of Enterobacterales and Pseudomonas aeruginosa collected from paediatric patients as part of the ATLAS global surveillance program: 2013-2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5331;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro Activities of ceftazidime-avibactam and comparator agents against Enterobacterales and Pseudomonas aeruginosa from Israel collected through the ATLAS global surveillance programme 2013-2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5328;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro activities of ceftazidime-avibactam and comparator agents against Enterobacterales from Europe stratified by infection type from the ATLAS global surveillance programme 2016-2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5327;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro Activities of ceftazidime-avibactam and comparator agents against Enterobacterales from Europe stratified by region, ATLAS global surveillance programme 2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5326;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro Activities of ceftazidime-avibactam and comparator agents against Enterobacterales and Pseudomonas aeruginosa from Turkey collected through the ATLAS global surveillance programme 2013-2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5325;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro activities of ceftazidime-avibactam and comparator agents against Gram-negative isolates from China as part of the ATLAS global surveillance programme 2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5324;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa from central Europe and Israel: ATLAS global surveillance programme 2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5323;
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In vitro Activities of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa from Europe stratified by infection type: ATLAS global surveillance programme 2016-2018 ([VIRTUAL]) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_5322;